Value-Based Pricing

Health Technology Assessment…
Cancer

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Health Technology Assessment…
Measuring and Valuing Outcomes
Cancer

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Health Technology Assessment…
Value, Affordability, and…

Latest Research & Publications

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Uncertainty and Risk in HTA Decision Making

The Distribution of the EQ-5D-5L Index in Patient Populations

Improving Efficiency and Resource Allocation in Future Cancer Care

Four Case Studies to Explore the Added Value of Oxford AHSN

“New Age” Decision Making in HTA: Is It Applicable in Asia?

All Publications

Filter results by

Delivering the Triple Win: A Value-Based Approach to Pricing

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

Filter results by

Share on Mastodon